3 Investing Lessons From Dendreon
Dendreon, the maker of the the prostate cancer drug Provenge, has been marginalized by newer drugs from Johnson & Johnson, Medivation, and Astellas Pharma. What three valuable investing lessons can investors learn from Dendreon’s mistakes?
Keep an Eye on Ligand, Medivation, ChemoCentryx, and Teva Today
Ligand Pharmaceuticals, ChemoCentryx, Medivation, and Teva could make health care headlines today. Here's why.
Why Pay Royalties? Just Buy the Whole Company
Bayer would rather pay $2.4 billion for all of Algeta than shell out payments for its Xofiga prostate cancer drug.
Teva's High Hopes for Custirsen
Teva is losing patent protection on its multi billion cancer drug Copaxone in 2015 and that has the company increasingly reliant on its pipeline. The company expects Phase 3 data early next year for Custirsen, a prostate drug it hopes will offset some of Copaxone's expected sales drop.